Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Epigenetic activation of POTE genes in ovarian cancer.

Sharma A, Albahrani M, Zhang W, Kufel CN, James SR, Odunsi K, Klinkebiel D, Karpf AR.

Epigenetics. 2019 Feb;14(2):185-197. doi: 10.1080/15592294.2019.1581590. Epub 2019 Mar 4.

PMID:
30764732
2.

Expression of the POTE gene family in human ovarian cancer.

Barger CJ, Zhang W, Sharma A, Chee L, James SR, Kufel CN, Miller A, Meza J, Drapkin R, Odunsi K, Klinkebiel D, Karpf AR.

Sci Rep. 2018 Nov 20;8(1):17136. doi: 10.1038/s41598-018-35567-1.

3.

DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.

Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, Odunsi K, Karpf AR.

Epigenetics. 2015;10(8):736-48. doi: 10.1080/15592294.2015.1062206.

4.

PRAME expression and promoter hypomethylation in epithelial ovarian cancer.

Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, Bshara W, Odunsi K, Karpf AR.

Oncotarget. 2016 Jul 19;7(29):45352-45369. doi: 10.18632/oncotarget.9977.

5.

DNA Methylome Analyses Implicate Fallopian Tube Epithelia as the Origin for High-Grade Serous Ovarian Cancer.

Klinkebiel D, Zhang W, Akers SN, Odunsi K, Karpf AR.

Mol Cancer Res. 2016 Sep;14(9):787-94. doi: 10.1158/1541-7786.MCR-16-0097. Epub 2016 Jun 3.

6.

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.

Gambaro K, Quinn MC, Cáceres-Gorriti KY, Shapiro RS, Provencher D, Rahimi K, Mes-Masson AM, Tonin PN.

BMC Cancer. 2015 Mar 17;15:135. doi: 10.1186/s12885-015-1138-8.

7.

Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.

Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Taverna P, Karpf AR, Griffiths EA.

Epigenetics. 2015;10(3):237-46. doi: 10.1080/15592294.2015.1017198.

8.

Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.

Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi K, Karpf AR.

Clin Cancer Res. 2011 Apr 15;17(8):2170-80. doi: 10.1158/1078-0432.CCR-10-2315. Epub 2011 Feb 4.

9.

BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.

Woloszynska-Read A, James SR, Song C, Jin B, Odunsi K, Karpf AR.

Cancer Immun. 2010 Jul 23;10:6.

10.

The C-terminal common to group 3 POTES (CtG3P): a newly discovered nucleolar marker associated with malignant progression and metastasis.

Redfield SM, Mao J, Zhu H, He Z, Zhang X, Bigler SA, Zhou X.

Am J Cancer Res. 2013 Jun 20;3(3):278-89. Print 2013.

11.

A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation.

Guerrero K, Wang Z, Bachvarova M, Gregoire J, Renaud MC, Plante M, Bachvarov D.

Gynecol Oncol. 2012 Jun;125(3):720-6. doi: 10.1016/j.ygyno.2012.03.026. Epub 2012 Mar 21.

PMID:
22446619
12.

[Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].

Mao YN, Zeng LX, Li YH, Liu YZ, Wu JY, Li L, Wang Q.

Zhonghua Fu Chan Ke Za Zhi. 2017 Oct 25;52(10):687-696. doi: 10.3760/cma.j.issn.0529-567X.2017.10.008. Chinese.

PMID:
29060967
13.

Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.

Notaro S, Reimer D, Fiegl H, Schmid G, Wiedemair A, Rössler J, Marth C, Zeimet AG.

BMC Cancer. 2016 Aug 2;16:589. doi: 10.1186/s12885-016-2637-y.

14.

BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.

Link PA, Zhang W, Odunsi K, Karpf AR.

Cancer Immun. 2013;13:6. Epub 2013 Jan 22.

15.

DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11.

James SR, Cedeno CD, Sharma A, Zhang W, Mohler JL, Odunsi K, Wilson EM, Karpf AR.

Epigenetics. 2013 Aug;8(8):849-63. doi: 10.4161/epi.25500. Epub 2013 Jul 9.

16.

Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.

Dahl ES, Buj R, Leon KE, Newell JM, Imamura Y, Bitler BG, Snyder NW, Aird KM.

Mol Cancer Res. 2019 Aug;17(8):1710-1720. doi: 10.1158/1541-7786.MCR-18-1233. Epub 2019 May 20.

PMID:
31110157
17.

Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer.

Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR.

Clin Cancer Res. 2008 Jun 1;14(11):3283-90. doi: 10.1158/1078-0432.CCR-07-5279.

18.

POTE paralogs are induced and differentially expressed in many cancers.

Bera TK, Saint Fleur A, Lee Y, Kydd A, Hahn Y, Popescu NC, Zimonjic DB, Lee B, Pastan I.

Cancer Res. 2006 Jan 1;66(1):52-6.

19.

DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.

Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR.

Cancer Immun. 2007 Dec 21;7:21.

20.

LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients.

Akers SN, Moysich K, Zhang W, Collamat Lai G, Miller A, Lele S, Odunsi K, Karpf AR.

Gynecol Oncol. 2014 Feb;132(2):462-7. doi: 10.1016/j.ygyno.2013.12.024. Epub 2013 Dec 25.

Supplemental Content

Support Center